Physician profile

Aleida Hera-Jimenez

General Practice · Miami, FL

NPI 1649421058

$2,901.76

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for General Practice

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$115.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,183.68 2019-2024 Airsupra
Allergan, INC. $378.52 2019-2020
Pfizer INC. $351.04 2019
Sunovion Pharmaceuticals INC. $243.02 2019
Novo Nordisk INC $234.32 2021
Ironwood Pharmaceuticals, INC $133.47 2019
Amarin Pharma, INC. $130.85 2019
Gilead Sciences, INC. $124.99 2022
Boehringer Ingelheim Pharmaceuticals, INC. $121.87 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Aleida Hera-Jimenez

$2,901.76

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/74490/aleida-hera-jimenez

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.